Portola Pharmaceuticals Inc (PTLA)

33.50
NASDAQ : Health Care
Prev Close 32.16
Day Low/High 32.34 / 33.68
52 Wk Low/High 15.68 / 33.68
Avg Volume 1.23M
Exchange NASDAQ
Shares Outstanding 56.54M
Market Cap 1.82B
EPS -4.40
P/E Ratio N/A
Div & Yield N.A. (N.A)

Latest News

Synergy, Portola Still in My Sights

Synergy, Portola Still in My Sights

Both pharma companies are promising names that easily could become buyout targets.

Premarket Biotech Movers: Portola, Esperion, Medicines

Premarket Biotech Movers: Portola, Esperion, Medicines

Portola Pharmaceuticals, Esperion Therapeutics and Medicines were among the biotech stock movers in premarket trading on Friday.

First Week of September 15th Options Trading For Portola Pharmaceuticals (PTLA)

First Week of September 15th Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options become available this week, for the September 15th expiration.

Biotech Premarket Movers: SGMO, IPXL, PTLA

Biotech Premarket Movers: SGMO, IPXL, PTLA

Sangamo Therapeutics, Impax Laboratories and Portola Pharmaceutical are among the premarket movers in biotech.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

Biotech Poised for Rebound

Biotech Poised for Rebound

If M&A picks up and Trump doesn't tweet about excessively high drug prices, there should be bounce.

A Biotech Trio to Like Going Into 2017

A Biotech Trio to Like Going Into 2017

Egalet, Portola Pharmaceuticals and Amicus Therapeutics hold promise for improvement.

First Week of PTLA February 2017 Options Trading

First Week of PTLA February 2017 Options Trading

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the February 2017 expiration.

Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%

Portola Pharmaceuticals Stock Sees Short Interest Jump 13.4%

The most recent short interest data has been released for the 11/30/2016 settlement date, which shows a 693,347 share increase in total short interest for Portola Pharmaceuticals, Inc. , to 5,883,540, an increase of 13.36% since 11/15/2016.

Apple, Starbucks, Cisco: Doug Kass' Views

Apple, Starbucks, Cisco: Doug Kass' Views

Doug Kass shares his thoughts on a strange, possibly ominous day, and a 'ludicrous forecast.'

First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)

First Week of January 2017 Options Trading For Portola Pharmaceuticals (PTLA)

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the January 2017 expiration.

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Battered Pharma Stocks Bounce Back, Could Boost Retirement Portfolios

Pharma stocks have bounced back from their prior selloff, but whether they will continue their upward trend under a Donald Trump administration remains unclear.

Cisco, Allergan, Facebook: Doug Kass' Views

Cisco, Allergan, Facebook: Doug Kass' Views

Doug Kass shares his thoughts on the bond market's bounciness and stocks suffering election uncertainty.

First Week Of PTLA June 2017 Options Trading

First Week Of PTLA June 2017 Options Trading

Investors in Portola Pharmaceuticals, Inc. saw new options begin trading this week, for the June 2017 expiration.

Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients

Portola Pharmaceuticals Submits New Drug Application To U.S. FDA For Betrixaban For Extended Duration Prophylaxis Of Venous Thromboembolism In Acute Medically Ill Patients

If Approved, Betrixaban, an FDA Fast Track-Designated Therapy, Would Be First Anticoagulant for Hospital to Home Prevention of VTE in this High-Risk Patient Population

Schlumberger, Amazon, Apple: Doug Kass' Views

Schlumberger, Amazon, Apple: Doug Kass' Views

Doug Kass shares his thoughts on 'stuck' markets and on differing risk appetites and timeframes.